^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EphB4 inhibitor

    Related drugs:
    24d
    Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, University of Southern California | Terminated --> Active, not recruiting | Trial completion date: May 2019 --> Apr 2026
    Enrollment closed • Trial completion date
    |
    cisplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • sEphB4-HSA
    6ms
    Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | N=170 --> 103
    Enrollment closed • Enrollment change
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    8ms
    sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=23, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025 | Trial primary completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    EPHB4 (EPH receptor B4)
    |
    sEphB4-HSA
    8ms
    sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, AIDS Malignancy Consortium | Trial completion date: Jun 2026 --> Feb 2026
    Trial completion date
    |
    EPHB4 (EPH receptor B4)
    |
    sEphB4-HSA
    8ms
    Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (clinicaltrials.gov)
    P2/3, N=700, Recruiting, Vasgene Therapeutics, Inc | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    EPHB4 (EPH receptor B4)
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv) • sEphB4-HSA
    10ms
    P30CA014089: Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (clinicaltrials.gov)
    P2, N=42, Completed, University of Southern California | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2024 | Trial primary completion date: Mar 2025 --> Sep 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    11ms
    Site-Specific Competitive Kinase Inhibitor Target Profiling Using Phosphonate Affinity Tags. (PubMed, Mol Cell Proteomics)
    Using the site-specific strategy to examine the on- and off-targets of the Ephrin receptor (Eph) B4 inhibitor NVP-BHG712 showed binding to EphA2 with an IC50 of 17 nM and EphB4 with an IC50 of 20 nM...Expanding the search to other amino acids revealed that XO44, in addition to 745 lysines, also covalently linked 715 tyrosines, which significantly expands the competitive ABPP search space and highlights the added value of the site-specific method. Therefore, the presented approach, which can be fully automated with liquid handling platforms, provides a straightforward, valuable new approach for competitive site-specific kinase inhibitor target profiling.
    Journal
    |
    EPHB4 (EPH receptor B4)
    |
    BHG712
    11ms
    Inhibition of EphB4 Receptor Signaling by Ephrin-B2-Competitive and Non-Competitive DARPins Prevents Angiogenesis. (PubMed, Biochemistry)
    The competitive DARPin AB1 was additionally shown to inhibit vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-induced angiogenesis in vivo. In summary, we have isolated DARPins that exert antiangiogenic effects by specifically binding to EphB4 and may potentially lead to new cancer therapeutics.
    Journal
    |
    EPHB4 (EPH receptor B4)
    over1year
    Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (clinicaltrials.gov)
    P2/3, N=700, Not yet recruiting, Vasgene Therapeutics, Inc
    New P2/3 trial • IO biomarker
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv) • sEphB4-HSA
    over1year
    P30CA014089: Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, University of Southern California | Phase classification: P2a --> P2 | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    almost2years
    Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P2, N=170, Recruiting, University of Southern California | Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    over2years
    sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, University of Southern California | N=36 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    sEphB4-HSA